| 1 | The regulators of BCR signaling during B cell activation显示文摘B lymphocytes produce antibodies under the stimulation of specific antigens,thereby exerting an immune effect.B cells identify antigens by their surface B cell receptor(BCR),which upon stimulation,directs the cell to activate and differentiate into antibody generating plasma cells.Activation of B cells via their BCRs involves signaling pathways that are tightly controlled by various regulators.In this review,we will discuss three major BCR mediated signaling pathways(the PLC-g2 pathway,PI3K pathway and MAPK pathway)and related regulators,which were roughly divided into positive,negative and mutual-balanced regulators,and the specific regulators of the specific signaling pathway based on regulatory effects. | Yue Wen Yukai Jing Lu Yang Danqing Kang Panpan Jiang Na Li Jiali Cheng Jingwen Li Xingbo Li Zican Peng Xizi Sun Heather Miller Zhiwei Sui Quan Gong Boxu Ren Wei Yin Chaohong Liu | 2019 | Blood Science2019，1，2： | 0 |
| 2 | A naturally derived small molecule compound suppresses tumor growth and metastasis in mice by relieving p53-dependent repression of CDK2/Rb signaling and the Snail-driven EMT显示文摘The tumor suppressor protein p53 is central to cancer biology,with its pathway reactivation emerging as a promising therapeutic strategy in oncology.This study introduced LZ22,a novel compound that selectively inhibits the growth,migration,and metastasis of tumor cells expressing wild-type p53,demonstrating ineffectiveness in cells devoid of p53 or those expressing mutant p53.LZ22’s mechanism of action involves a high-affinity interaction with the histidine-96 pocket of the MDM2 protein.This interaction disrupted the MDM2-p53 binding,consequently stabilizing p53 by shielding it from proteasomal degradation.LZ22 impeded cell cycle progression and diminished cell proliferation by reinstating the p53-dependent suppression of the CDK2/Rb signaling pathway.Moreover,LZ22 alleviated the p53-dependent repression of Snail transcription factor expression and its consequent EMT,effectively reducing tumor cell migration and distal metastasis.Importantly,LZ22 administration in tumor-bearing mice did not manifest notable side effects.The findings position LZ22 as a structurally unique reactivator of p53,offering therapeutic promise for the management of human cancers with wild-type TP53. | REN Boxue LI Yang DI Lei CHENG Ranran LIU Lijuan LI Hongmei LI Yi TANG Zhangrui YAN Yongming LU Tao FU Rong CHENG Yongxian WU Zhaoqiu | 2024 | Chinese Journal of Natural Medicines2024，22，2： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员